Alliance Bernstein - AB Corporate Bond ETF
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Bonds
- Address
- 501 Commerce Street Nashville TN United States of America 37203
- IPO Date
- Dec 13, 2023
- CIK
- 0001372514
- Website
- alliancebernstein.com
- Similar Companies
- Business
- The fund seeks to achieve its investment objectives by allocating, under typical market conditions, at least eighty percent of its total assets, including any capital secured through borrowing for investment purposes, into high-quality, fixed-income instruments issued by corporations. These corporate entities may encompass business organizations where a sovereign or governmental body holds either a direct or indirect stake, potentially including a controlling ownership interest. This actively managed exchange-traded fund, launched in December 2023, aims to maximize overall returns through a combination of consistent income and long-term capital growth. It utilizes a quantitative, bottom-up security selection method, focusing on U.S. dollar-denominated investment-grade corporate bonds across various maturities and durations.
AllianceBernstein Launches 5 New Active ETFs
EYEG Stock Price: Why It Substantially Increased
7 Best Penny Stocks to Buy on the Nasdaq for October
Best Penny Stocks to Buy Right Now? 3 to Watch in October
Penny Stocks For Your Biotech Watch List In September 2021
4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507%
EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation
Top Penny Stocks You Need to Know About Right Now
EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update
EYEG Stock Price Falls Over 14% Pre-Market: Why It Happened
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
EYEG Stock Increases Over 135% Pre-Market: Why It Happened
Why Shares Of Eyegate Pharmaceuticals Spiked After Hours Monday
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D.
EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study
EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update
EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation